H K Roy
Overview
Explore the profile of H K Roy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
12.
13.
14.
Senapati S, Chaturvedi P, Sharma P, Venkatraman G, Meza J, El-Rifai W, et al.
Br J Cancer
. 2008 Sep;
99(6):949-56.
PMID: 18781152
MUC4 is a large, heavily glycosylated transmembrane mucin, that is implicated in the pathogenesis of various types of cancers. To date, no extensive study has been done to check the...
15.
Wali R, Roy H, Kim Y, Liu Y, Koetsier J, Kunte D, et al.
Gut
. 2005 Apr;
54(5):654-60.
PMID: 15831911
Background: Increased premalignant epithelial microvascular blood content is a common theme in neoplastic transformation; however, demonstration of this phenomenon in colon carcinogenesis has been stymied by methodological limitations. Our group...
16.
17.
Zack D, DiBaise J, Quigley E, Roy H
Am J Gastroenterol
. 2001 Nov;
96(10):3004-8.
PMID: 11693339
Objective: Implementation of colorectal cancer (CRC) screening with widely available techniques can result in a significant reduction in CRC-related mortality. Clinical practice paradigms are often ingrained in physicians during residency....
18.
Roy H, DiBaise J, Black J, Karolski W, Ratashak A, Ansari S
FEBS Lett
. 2001 May;
496(2-3):143-6.
PMID: 11356199
Recent experimental evidence suggests that polyethylene glycol (PEG) is a highly effective chemopreventive agent against colon cancer; however, the mechanism(s) remain largely unexplored. To further elucidate this issue, we evaluated...
19.
Roy H, Karoski W, Ratashak A, Smyrk T
Br J Cancer
. 2001 May;
84(10):1412-6.
PMID: 11355956
Treatment of MIN mice with the nonsteroidal anti-inflammatory drug, nabumetone, resulted in a dose-dependent suppression of intestinal tumorigenesis. In both the uninvolved MIN mouse colonic epithelium and HT-29 colon cancer...
20.
Roy H, Karolski W, Ratashak A
Int J Cancer
. 2001 Apr;
92(4):609-15.
PMID: 11304699
Use of non-steroidal anti-inflammatory drugs (NSAIDs) for chemoprevention of colon cancer has been hindered by their potential gastro-intestinal toxicity. Nabumetone, which is approximately 10 to 36 times safer than conventional...